{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:56:19Z","timestamp":1791910579787,"version":"4.3.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T00:00:00Z","timestamp":1469923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>Use of medications with anticholinergic activity is widespread in older adults. Several studies have highlighted that anticholinergic use may be associated with an increased risk of dementia. The objective of this narrative review is to describe and evaluate studies of anticholinergic medication use and dementia and provide practical suggestions for avoiding use of these medications in older adults. A comprehensive review of the literature, citations from recent reviews and the author\u2019s personal files was conducted. Four studies were found that evaluated anticholinergic use and dementia as the primary outcome. Three studies focused on overall anticholinergic medication use and reported a statistically significantly increased risk of Alzheimer\u2019s disease or dementia. In one study, dementia risk was primarily found with higher cumulative doses; people using anticholinergic medications at the minimum effective dose recommended for older adults for at least 3 years were at highest risk. In contrast, a study conducted in nursing-home residents with depression did not find that paroxetine [a highly anticholinergic selective serotonin reuptake inhibitor antidepressant, (SSRI)] increased risk for dementia compared with other SSRIs (without anticholinergic activity). Further study is needed to understand the mechanism by which anticholinergic medications may increase risk. In conclusion, there is evidence from three observational studies suggesting that anticholinergic medications may increase dementia risk. Given this potential risk and the myriad of other well-known adverse effects (i.e. constipation, blurred vision, urinary retention, and delirium) associated with anticholinergic medications, it is prudent for prescribers and older adults to minimize use of these medications and consider alternatives when possible.<\/jats:p>","DOI":"10.1177\/2042098616658399","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T20:23:55Z","timestamp":1468959835000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":64,"title":["Anticholinergic medication use and dementia: latest evidence and clinical implications"],"prefix":"10.1177","volume":"7","author":[{"given":"Shelly L.","family":"Gray","sequence":"first","affiliation":[{"name":"School of Pharmacy, Health Sciences Building, H-361D Box 357630, University of Washington, Seattle, WA 98195-7630, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Hanlon","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, School of Medicine, Department of Pharmacy and Therapeutics, School of Pharmacy, and Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA; Geriatric Research, Education, and Clinical Center and Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,31]]},"reference":[{"key":"bibr1-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03923.x"},{"key":"bibr2-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13702"},{"key":"bibr3-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38740.439664.DE"},{"key":"bibr4-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201500011"},{"key":"bibr5-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2007.10.001"},{"key":"bibr6-2042098616658399","unstructured":"Brown J., Laiken N. (2011) Chapter 9, Muscarinic receptor agonists and antagonists. In: Brunton L. L., Chabner B., Knollmann B. (eds), Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill. Available at: www.accessmedicine.com\/content.aspx?aID=16660596 (accessed 30 January 2016)."},{"key":"bibr7-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.02.005"},{"key":"bibr8-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e7f2ab"},{"key":"bibr9-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.229"},{"key":"bibr10-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01737.x"},{"key":"bibr11-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1499-3"},{"key":"bibr12-2042098616658399","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2015.240"},{"key":"bibr13-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245172"},{"key":"bibr14-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244414"},{"key":"bibr15-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182487825"},{"key":"bibr16-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.087"},{"key":"bibr17-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.7663"},{"key":"bibr18-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1097\/00013614-199603000-00006"},{"key":"bibr19-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13807"},{"key":"bibr20-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-010-0156-4"},{"key":"bibr21-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.30"},{"key":"bibr22-2042098616658399","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2012.564"},{"key":"bibr23-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gls176"},{"key":"bibr24-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12140"},{"key":"bibr25-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(92)90017-G"},{"key":"bibr26-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001362"},{"key":"bibr27-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10639"},{"key":"bibr28-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1177\/002383099200500203"},{"key":"bibr29-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0580"},{"key":"bibr30-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0158-4"},{"key":"bibr31-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.160"},{"key":"bibr32-2042098616658399","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-012-0556-0"},{"key":"bibr33-2042098616658399","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-110935"},{"key":"bibr34-2042098616658399","unstructured":"World Health Organization (2012). Dementia: a public health priority. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/75263\/1\/9789241564458_eng.pdf (accessed 21 January 2016)."},{"key":"bibr35-2042098616658399","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150290"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098616658399","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2042098616658399","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098616658399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:38:21Z","timestamp":1777592301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2042098616658399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,31]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1177\/2042098616658399"],"URL":"https:\/\/doi.org\/10.1177\/2042098616658399","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,31]]}}}